The regulation and mechanisms of EGFR-mediated apoptosis in MDA-MB-468 cells. by Jackson, Nicole Marion
University of Louisville
ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
8-2015
The regulation and mechanisms of EGFR-
mediated apoptosis in MDA-MB-468 cells.
Nicole Marion Jackson
University of Louisville
Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Master's Thesis is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted
for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository.
This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.
Recommended Citation
Jackson, Nicole Marion, "The regulation and mechanisms of EGFR-mediated apoptosis in MDA-MB-468 cells." (2015). Electronic
Theses and Dissertations. Paper 2216.
https://doi.org/10.18297/etd/2216
THE REGULATION AND MECHANISMS OF EGFR-MEDIATED APOPTOSIS 





Nicole Marion Jackson 
 





A Thesis  
Submitted to the Faculty of the  
School of Medicine of the University of Louisville  
In Partial Fulfillment of the Requirements  




Master of Science  





Department of Pharmacology and Toxicology 












THE REGULATION AND MECHANISMS OF EGFR-MEDIATED APOPTOSIS 
IN MDA-MB-468 CELLS 
 
By 
Nicole Marion Jackson 
B.A., Cheyney University of Pennsylvania, 2012 
Thesis Approved on 
 
July 21, 2015 
 
By the following Thesis Committee: 
 
___________________________________ 


























This thesis is dedicated to my family. 





I would like to acknowledge and thank my mentor, Dr. Brian P. Ceresa. He 
has been and continues to be supportive, encouraging, and patient with both my 
scientific endeavors and with me. I would also like to thank all of the Ceresa lab 





THE REGULATION AND MECHANISMS OF EGFR-MEDIATED APOPTOSIS 
IN MDA-MB-468 CELLS 
 
Nicole Marion Jackson 
 
July 21, 2015 
 
 
Background: The Epidermal Growth Factor Receptor (EGFR) is a 170-
kilodalton transmembrane protein that belongs to the ErbB family of receptor 
tyrosine kinases. Upon ligand-mediated activation, the EGFR responsible for cell 
growth, proliferation, and tissue homeostasis in epithelial cells; however, the 
EGFR is overexpressed in many human malignancies including MDA-MB-468 
cells, a metastatic breast epithelial cell line. Previous studies have indicated that 
within the MDA-MB-468 cell line, receptors at the cell surface promote cell 
growth when activated with Epidermal Growth Factor (EGF) ligand. Activated 
receptors that are internalized to the endosomes however induce apoptosis. This 
contrasting response at different cellular locations is defined as spatial regulation. 
The overarching research goal of this thesis is to better understand the spatial 
regulation within these cells, and identify the effector proteins responsible for the 
difference in signals emanated at the cell membrane versus intracellularly. The 
goals of this thesis were to first determine whether other EGFR ligands, 
Betacellulin (BTC) and Transforming Growth Factor-alpha (TGFA), are able to 
induce apoptosis in the MDA-MB-468 cell line. The second goal was to identify 
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effectors downstream of EGFR activation that could have potential implications in 
EGFR-mediated apoptosis.  Methods: An MTT assay was conducted in order to 
evaluate the viability of the MDA-MB-468 cells after treatment and activation with 
3 EGFR ligands: EGF, BTC, or TGFA. EGF activity was measured as a function 
of receptor phosphorylation. Western blot analysis was conducted after MDA-
MB-468 cell exposure to increasing concentrations of the three ligands. This was 
done in order to identify any variances or similarities in phosphorylation patterns 
amongst the three ligands.  Lastly, cell morphology was observed after the cells 
were exposed to 16 nM concentrations of each ligand for 24 hours. A different 
approach to assessing EGFR spatial regulation was then employed. MDA-MB-
468 cells were subjected to time course and dose response experiments, prior to 
the ultimate assessment of various different effectors. Results: All ligands 
induced dose dependent decreases in cell viability. All three ligands signaled 
through the EGFR, as measured by receptor phosphorylation, with similar 
phosphorylation patterns. Western blot analyses indicate a dose dependent 
increase in EGFR phosphorylation in response to all ligands. MDA-MB-468 cells 
were round in morphology at 24-hour time points with exposure to high 
concentrations of all ligands.  An effector screening was conducted, which 
resulted in the discovery of upregulated STAT3 activity, preferentially with high 
EGF concentrations. This suggests the potential for STAT3 to mediate apoptosis, 
and be spatially regulated in MDA-MB0468 cells. After confirming the 
upregulation of STAT3 in an EGFR dependent manner, commercially available 
inhibitors of STAT3 were employed; however the inhibitors exhibited non-specific 
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effects, in vitro. Conclusions: These data suggest that EGFR signaling in MDA-
MB-468 cells is not ligand specific, and that activation and internalization of the 
receptor in this cell line with any endogenous ligand will result in cell death. The 
results indicate a potential role of STAT3 in EGFR-induced apoptosis. Future 
experiments will entail employing siRNA targeting STAT3 in order to determine 
the role of STAT3 in EGFR-induced apoptosis. 
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BACKGROUND AND INTRODUCTION 
 
The epidermal growth factor receptor (EGFR) is a cell surface receptor 
that is expressed in almost every tissue of the body and plays critical roles in 
development and tissue homeostasis.  Further, many cancers are characterized 
by hyper-activated EGFR signaling, either due to overexpression of the receptor 
or somatic activating mutations of the receptor. These perturbations in EGFR 
expression and/or activation are associated with poor patient prognosis. Over the 
last 15-20 years, there has been a concerted effort to develop cancer 
therapeutics that specifically target the aberrant EGFRs, with the goal of 
inhibiting the progression of those cancers. Understanding the basic cell biology 
of the EGFR helps to understand its implications, and define its typical role in 
normal cell biology.  
In order to better understand the function of the EGFR, it is best to start 
with the discovery of one of the principal ligands that initiates its activity. Dr. 
Stanely Cohen isolated and discovered its endogenous ligand, Epidermal Growth 
Factor (EGF) from murine submaxillary glands in the early 1960’s. Frozen 
submaxillary glands were obtained from mice and homogenized in acetic acid, 
prior to being frozen in a dry ice-alcohol bath. The material was then thawed and 
subjected to a series of ultra-centrifugations at 100,000 x g, and acetic acid 
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washes. The newly formed pellet was then subjected to size exclusion, and ion 
exchange chromatography for purification [1]. Amino acid analysis of the purified 
product revealed that EGF is a 53 amino acid residue polypeptide, containing 
three internal disulfide bonds, as depicted in Figure 1. 
Dr. Cohen observed that injecting the purified, crude, submaxillary gland 
preparations into newborn mice stimulated growth of embryonic neurons and 
induced precocious eyelid opening.  Having identified a growth factor that was 
able to initiate some very specific physiological responses, the next goal was to 
identify the receptor. In 1978, he and Dr. Graham Carpenter were able to identify 
the presence of the 170 kilodalton EGFR specific for EGF ligand through the use 
of radiolabeled (125 I-labeled) EGF ligand in A-431 cells, a human epidermoid 
carcinoma cell line. They reported increased 32P incorporation in the A-431 cells 
in response to EGF ligand stimulation, suggesting that phosphorylation of EGFR 
components might be critical for its function [2]. In 1982, Dr. Cohen proceeded to 
then successfully isolate and purify the EGFR from A-431 cells, and from normal 
mouse liver cells by means of affinity chromatography. Purification of the 
receptor aided in the confirmation that the EGFR was able to bind 125 I-labeled 
EGF, and that the receptor possessed ligand stimulated, intrinsic kinase activity, 
which was responsible for auto-phosphorylation of tyrosine residues, upon 
binding of EGF. This particular study also confirmed that the receptor in normal 
liver cells had biochemical similarities to receptors found in the carcinoma cell 
line [3]. The contributions of Dr. Cohen and Dr. Carpenter have allowed for  
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Figure 1. The amino acid sequence of EGF ligand, isolated and purified from 




subsequent studies to unveil further information about the receptor, including its 
physiology, function, and regulation. 
Another huge leap in our understanding of the molecular mechanism of 
EGFR-mediated signaling came in 1984 when Ullrich and colleagues used the 
newly identified tools of molecular biology to clone the human EGFR.  From this 
report, a model (which has been modified numerous times over the years) was 
generated that described the functional domains of the EGFR.  
The EGFR is comprised of three major domains: 1) an extracellular, ligand 
binding domain with cysteine rich regions, 2) a cytosolic, intrinsic kinase domain, 
and 3) a cytosolic domain containing tyrosine residues [4]. Studies by Lax et al. 
devised a method utilizing 125 I-labeled EGF to label the EGFR for subsequent 
isolation, and cleavage through use of Cyanogen Bromide (CNBr). Site-specific 
antibodies were then used to identify certain residues (293 and 543) that are 
critical for the function of the receptor. On the basis of amino acid sequence 
conservation, it was then determined that the extracellular domain was 
comprised of 600 amino acids, and could be divided into 4 sub-domains [5]. 
Domains I and III are ligand binding regions, with 37% homology that physically 
bind the ligand. Domains II and IV are rich in cysteine, and have 17% amino acid 
homology that interfaces with other receptors for dimerization [6, 7].   
The model of how these domains come together is based on 
crystallographic analysis that was done by the Lemmon laboratory. In the 
unliganded state, the cysteine-rich domains of a monomeric receptor bind to one 
another through an intramolecular interaction.  Upon the introduction of ligand, 
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the receptor undergoes a conformational change such that both ligand binding 
domains bind the ligand and disrupt the interaction between the two cysteine rich 
domains.  The exposure of cysteine rich domain I then can interact with the 
corresponding domain with another EGFR to form a dimer. Ligand binding also 
brings about a conformational change that activates the intrinsic kinase domain, 
which then leads to autotransphosphorylation of the cytosolic tyrosine residues 
[8]. The kinase domain of each receptor moiety will phosphorylate tyrosine 
residues on its adjacent dimer partner by a conformational change in the receptor 
that places the tyrosine substrate in access to the kinase domain. These 
phosphotyrosines then serve as docking sites for various cytoplasmic enzymes, 
known as effector molecules. By docking to the phosphotyrosines, these 
effectors become activated and modulate various cellular processes that 
contribute to the overall cell biology [9]. For example, activation of the EGFR by 
EGF leads to activation of the Janus Kinase (JAK) tyrosine kinase in the cytosol. 
The JAK protein then proceeds to phosphorylate and activate the signal 
transducers and activators of transcription (STAT) proteins [10]. This JAK/STAT 
signaling cascade is a pathway implicated in cell survival responses [11]. 
Activation of alternative downstream signaling cascades by the EGFR induces 
known responses for cellular differentiation, proliferation, migration, and 
protection from apoptosis [12]. 
Although the EGFR is expressed at the cell surface of many normal cells, 
and is critical for animal development and cellular homeostasis, it is often 
mutated and/or hyper-expressed in a number of human malignancies [13]. In a 
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study conducted by Real et al., mouse monoclonal antibodies specific for the 
EGFR were used to assess the distribution of the receptor in various human cell 
and tissue types. These studies have confirmed EGFR expression in normal 
stomach, bladder, colon, esophageal, and lung tissue; however, no expression 
was determined in normal brain tissue or skeletal muscle [14]. In regard to 
malignant cells and tissue, the EGFR has shown to be hyper-expressed in colon, 
kidney, lung and sarcoma cancers; however, it is non-prevalent in primary 
melanoma [14] and gliosarcoma malignancies [15].  
In the analysis of large populations of cancers with EGFR mutations, one 
of the most common mutations entails a deletion of exons 2-7 of the EGFR gene 
that removes virtually the entire extracellular domain of the receptor. In the 
absence of a ligand binding domain or cysteine rich domains that have 
intramolecular binding that prevents dimerization, this receptor is free to 
associate with other mutant receptors and is constitutively active. This mutant 
receptor is referred to as EGFRvIII, and is substantially expressed in patients 
with glioblastoma malignancies [16, 17]. Mutated tyrosine residues of the EGFR 
at the cytosol have also been shown to induce aberrant signaling as well as drug 
resistance in cancers characterized by hyper-expression of the EGFR [18, 19]. In 
addition to the EGFR itself, studies have shown that alterations in EGFR ligand 
expression can hinder certain tissue physiology. Luetteke et al. bred knockout 
mice that lacked endogenous expression of various, endogenous EGFR ligands. 
Pups born to these knockout mice were runted, and showed stunted growth and 
survival. These data provide confirmation of a requirement for EGFR ligands to 
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initiate receptor signaling in order for proper development of the mouse 
mammary gland [20]. Overall, it can be inferred that regulation of tyrosine 
phosphorylation as well as endogenous EGFR ligands are both critical for proper 
signaling and modulation of cellular effects of the activated receptor. 
Numerous cellular processes play a role in controlling EGFR activity. Chief 
among these is ligand-mediated endocytosis. Co-incident with ligand binding to 
the EGFR and activation of the intrinsic kinase domain, the ligand:receptor 
complex is internalized into the cell in either a clathrin-mediated, or clathrin-
independent manner. Clathrin-coated vesicles were first identified in osteocytes 
[21], and then later in neurons [22]. In 1975, Barbara Pearse biochemically 
characterized these clathrin-coated vesicles as transport vesicles upon isolating 
and purifying them from pig brains prior and analyzing their physical properties 
via electron microscopy. She described these vesicles as intracellular vesicles 
with unique “coats” on their cytoplasmic surfaces [23]. Her discovery serves as 
the foundation of biochemical studies entailing clathrin-mediated endocytosis and 
membrane trafficking in general. 
 Sigismund et al. stimulated receptor activation with EGF for 2 minutes in 
HeLa cells prior to immunostaining and subjecting the fixed cells to 
immunoelectron microscopy. Immunoelectron microscopy allowed for viewing 
and imaging of the immunostained cells in their various compartments during 
EGFR mediated endocytosis [24]. These studies, as well as subsequent studies, 
revealed that Clathrin-mediated EGFR endocytosis is observed at all ligand 
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concentrations, where as with higher concentrations of ligand, (10-100 ng/mL) 
the receptor undergoes Clathrin-independent endocytosis via caveolae [25, 26].  
Once internalized within the cell, the EGFR is subjected to the endocytic 
pathway, a pathway responsible for sorting and determining the ultimate fate of 
the internalized ligand:receptor complex. An intermediate vesicle containing the 
ligand:receptor complex fuses with an early endosome. The mildly acidic 
environment of the early endosome (pH 6) allows for certain EGFR ligands (EGF 
and transforming growth factor–alpha (TGFA)) to dissociate from the EGFR, 
should the ultimate fate of the receptor be recycling back to the plasma 
membrane [27]. From here, the unbound-receptor will recycle back to the cell 
membrane via recycling endosomes for additional ligand binding and signaling. 
These recycling endosomes, slightly acidic at pH 6.4, are generally located within 
the cell, and are centered around the microtubule-organizing center [28]. These 
recycling endosomes exhibit tubular-vesicular morphology, which suggests 
dynamic trafficking activity and supports their involvement with the underlying 
connection of endocytosis with exocytosis [29, 30]. Should the ligand:receptor 
complex remain inside of the early endosome, however, the early endosome will 
mature into a late endosome with the complex intact. The late endosome then 
fuses with the lysosome just prior to the ultimate degradation of the 
ligand:receptor complex [31]. This endocytic pathway is essential for regulating 
the activity of the EGFR, both temporally and spatially. Temporally, meaning that 
the time it takes the receptor to transverse the entire endocytic pathway will 
ultimately dictate the duration of its signaling. Spatially, in regard to the fact that 
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at different subcellular locations, the receptor will interact with different effector 
proteins, activating different signaling cascades [32]. 
Due to hyper-expression of the EGFR in a number of human 
malignancies, including kidney, breast, pancreatic, and cervical cancers [33], the 
correlation between signaling by the EGFR and the endocytic pathway has 
important implications in both receptor tyrosine kinase and cancer biology [32]. 
One approach utilized to assess this correlation involves studying EGFR 
signaling and endocytosis upon activation with different ligands. Currently, there 
are seven identified growth factor proteins that are able to bind to and activate 
the EGFR: these include EGF, amphiregulin (AREG), betacellulin (BTC), epigen 
(EPGN), epiregulin (EREG), heparin-binding EGF-like growth factor (HBEGF), 
and TGFA [34]. Although each of these ligands stimulates EGFR activation and 
internalization, they yield diverse effects on endocytic sorting [35]. This 
information can be used advantageously to assess the differential effects and 
regulatory mechanisms different ligands have on EGFR signaling. One of the 
critical components of this thesis entails determining if EGFR ligands have 
differential effects on EGFR-mediated apoptosis. 
EGF is a 53 amino acid, 6.4 kilodalton (kDa) protein that has been shown 
to be involved in regulation of cellular proliferation in mammals [36, 37]. Similarly 
to EGF, TGFA ligand contains 50 amino acids and has a molecular weight of 
approximately 6 kDa. Both EGF and TGFA bind the EGFR; however, TGFA 
binds with 10-30 fold less affinity to the receptor in rat hepatocytes in comparison 
to EGF. Thoresen et al. isolated hepatocytes from Wistar rats prior to stimulating 
! 10!
the cells with increasing concentrations of 125 I-EGF and 125 I-TGFA. Surface 
binding curves after 24-hour ligand exposure exhibit a binding affinity of 11.9 nM 
for TGFA, and 0.42 nM for EGF. The data within this study suggest that the two 
ligands compete for a single population of binding sites in rat hepatocytes, 
although EGF has a significantly higher binding affinity for the EGFR than TGFA 
[38]. It is important to note that TGFA is synthesized and most prevalent in 
cancer cells, and cells transformed by oncogenes and retroviruses [39]. BTC, a 
slightly larger ligand (9 kDa) comprised of 80 amino acids, was originally isolated 
from mouse insulinoma cells, and is able to activate EGFR and ErbB4 [40]. 
Studies utilizing 125 I-BTC in 	fibroblasts confirm a binding affinity of 
0.5 nM for the EGFR, and suggest that the preferred receptor for BTC is the 
EGFR [41]. 
All three of these ligands are able to bind to the EGFR, and stimulate 
kinase activity; however, they differ in regard to their binding affinities to the 
EGFR, and their ultimate fates upon endocytosis and endocytic trafficking. In 
order to compare ligand internalization upon EGFR stimulation, Roepstorff et al. 
used an approach of pre-binding various EGFR ligands on ice to view the 
synchronized wave of receptor internalization. After determining optimal 
incubation time using 125 I-EGF, HEp2 cells were incubated with increasing ligand 
concentrations for 100 minutes. The amount of total cell surface receptors was 
then determined by means of FACS analysis. These data show that EGF and 
BTC ligands both target the EGFR for lysosomal degradation. In contrast, TGFA 
almost always leads to recycling of the EGFR to the cell membrane within 90 
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minutes of ligand exposure [35]. EGF and BTC can both withstand the acidic 
conditions of the endosomes, dissociating at around pH 5. In contrast, TGFA 
rapidly dissociates from the receptor at pH 7, and is unable to withstand the 
acidic environment of the early endosome. This therefore causes the ligand-free 
receptor to recycle back to the cell membrane [35, 42]. The fate of the EGFR, 
whether it is for degradation or recycling, is critical for its duration of signaling, 
which will vary based on different ligands bound to the receptor. This has 
ultimate implications in the initiation different signaling cascades. 
In summary, the EGFR is a transmembrane receptor tyrosine kinase with 
critical implications in normal cell growth, proliferation, wound healing, and tissue 
homeostasis. It is regulated in both a spatial and a temporal manner. Trafficking 
of the receptor can vary depending on the ligand it is bound to. The EGFR is 
however hyperexpressed in mammalian cancer [33]. There is more known about 
EGFR cell biology in non-malignant tissue, more so than in cancer cells. 
Research has shown that pharmaceutically available EGFR inhibitors provided to 
cancer patients triggers autophagy, a degradative process that actually helps 
cancer cells withstand nutrient-poor conditions [43]. The primary focus of this 
thesis is to better understand the function and role of the EGFR in cell growth 
and apoptosis in cancer. Doing so will require determining if different ligands 
have varying effects on cell viability and apoptosis. It is also of interest to identify 
specific proteins with direct implications in EGFR-induced apoptosis. This will 
help to develop better, more efficacious therapy for cancers that hyperexpress 
the receptor.  
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CELL DEATH AND APOPTOSIS 
 
 The EGFR is typically associated with cell growth, development and tissue 
homeostasis; however, it has been also known to mediate cell death in cancers 
that hyperexpress EGFRs [44-46]. Using a cell line that undergoes EGFR-
mediated apoptosis uniquely allows for the enlightenment of the biochemical 
regulation of signaling by using a sensitive, tractable and irreversible readout. 
These findings can be used to better understand other signaling pathways and 
biological responses to cell growth, and its counterpart, programmed cell death.  
The term apoptosis entails the process of programmed cellular death in 
both single-cellular and multicellular organisms. Programmed cell death refers to 
the time and position of cell death during development of a given organism. It has 
many functions during the development process, including adjusting and deleting 
cell numbers [47]. Both apoptosis and programmed cell death are normal 
processes in growth, development and aging as a homeostatic mechanism for 
proper maintenance of cell populations in tissues [48]. John Kerr first used the 
term apoptosis in 1972, in order to describe a morphologically distinct form of cell 
death. Through the use of light and electron microscopy, morphological events 
that occur during apoptosis have been identified [49]. The process of apoptosis 
entails structural changes that take place in two distinct stages: During stage 
one, the cell rounds in shape, shrinks, and breaks into well-preserved fragments.
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Its nuclear and cytoplasmic compartments condense, causing the cellular 
organelles to become more tightly packed as well as fragmented [48, 50]. 
Pyknosis, or chromatin condensation, is a key characteristic component of 
apoptosis [48]. During the second stage, the apoptotic body, a small sealed 
membrane that is released by cells undergoing programmed cell death [51], is 
taken up by other cells just prior to being degraded and broken down within the 
lysosome [50]. This helps to remove any superfluous material, and provide 
nutrients that were once in the apoptotic cell to the cell that is viable [52].  The 
apoptotic process is a critical component in normal human embryonic 
development, and tissue homeostasis in all living organisms [48, 53]. However, 
cancer cells often have the ability to avoid apoptosis, and continue to proliferate 
[54]. This dysregulation of apoptosis is associated with many malignancies, 
including breast, ovarian and colon cancers [55, 56].  Consequently, this can lead 
to cellular accumulation within a given organism, creating a permissive 
environment for genetic instability and oncogene activation. These events are 
known to disrupt cell turnover and function, as well as damage and kill healthy, 
viable cells [57].  
Alternatively to apoptosis, cell death can also occur in a necrotic manner. 
Necrosis is considered to be a degradative, toxic process that consequently 
induces cell swelling [58, 59], opposite of apoptosis [58].  Necrosis is an 
uncontrolled process and requires no energy input. It typically affects a large 
population of cells, and causes inflammation, in vivo. Conversely, apoptosis is a 
controlled and energy-dependent process that does not induce inflammation, and 
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can occur in individual cells as well as large clusters of cells [48]. The manner of 
cell death by either necrosis or apoptosis depends on the nature of the tissue 
type, its developmental stage, and the cell death signal itself [60]. 
There are several biochemical modifications of apoptotic cells, which can be 
used to help differentiate and identify them. Such modifications include DNA 
breakdown, phagocytic recognition, and protein cleavage and cross-linking [61]. 
The caspase proteins are a family of aspartic acid-specific proteases that have 
proteolytic activity and are major effectors of apoptosis [48, 62]. They are 
normally synthesized as inactive precursors, or pro-enzymes, and only become 
activated upon the induction of apoptosis. The pro-enzymatic form gets cleaved 
and activated by other caspases, initiating a signaling cascade as well as 
apoptosis induction [62]. Currently, there are 14 caspases that have been 
identified [63]. These are categorized into three subgroups based on their 
function within the signaling cascade.  Initiator capsases (caspases 2, 8, 9, and 
10) begin the cascade by activating and cleaving the executioner caspases 
(caspases 3, 6, and 7) at aspartic acid residues. Once executioner caspases are 
activated, they cleave and activate other cellular substrates, such as poly (ADP-
ribose) polymerase (PARP), ultimately starting the apoptotic process [48, 64]. 
The third subgroup of caspase proteins includes caspases 1, 4 and 5, which 
have more active roles in cytokine maturation [65].  
Mechanistically, apoptosis is quite complex, involving two main pathways: 




Figure 2. Schematic representation of apoptotic events. (Adapted from 




entails initiating apoptosis via transmembrane receptor-mediated interactions. 
These receptors are known as “death receptors”, and are members of the tumor 
necrosis factor (TNF) receptor family [66]. Members of this family have a “death 
domain”, which is a cytoplasmic domain comprised of 80 amino acids. 
The death domain of TNF receptors is primarily responsible for relaying 
signals for cell death from the cell membrane to the intracellular signaling 
pathways [48, 67]. Upon ligand binding, adapter proteins are recruited to the 
death receptors at corresponding death domains. For instance, Fas ligand, a 
ligand with a known biological function of inducing apoptosis [68], binds to the 
Fas receptor, a member of the TNF receptor family. This ligand-receptor 
interaction promotes the intracellular recruitment of the FADD adapter protein 
[69]. FADD then associates with procaspase-8, forming a death-inducing 
signaling complex (DISC). This then results in the auto-catalytic activation of 
caspase-8 from procaspase-8 [70]. The activated caspase-8 then activates 
executioner caspases, which leads to the induction of apoptosis. Defects in Fas 
ligand and Fas receptor are causes of various autoimmune diseases. It has been 
shown that upon knocking out the fas gene by homologous recombination, 
generalized lymphoproliferative disease (gld) can be completely recapitulated in 
mouse models [71]. Similarly, gld can be completely cured by simply expressing 
the normal fas gene in the same knockout mice [72]. These studies exhibit how 
critical Fas-induced apoptosis is to the regulation and cellular homeostasis of 
immunocompromised organisms.  
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The intrinsic signaling pathway of apoptosis initiates apoptosis in a non-
receptor mediated manner. This pathway entails mitochondrial- initiated events, 
involving certain stimuli that send intracellular signals to act on specific targets 
within the cell. These intercellular signals can be positive or negative signals.  
Negative signals often lead to withdrawal of certain growth factors, which fails to 
suppress death processes and essentially triggers apoptosis. On the other hand, 
positive signals include those for free radicals, toxins, and viral infections [48]. 
Apoptotic signals originating from the cell surface lead to the release of 
cytochrome c from the mitochondria into the cytosol, where it ultimately binds to 
the Apoptotic Protease Activation Factor-1 (Apaf-1). The binding of cytochrome c 
to Apaf-1 initiates apoptosome formation, which catalyzes the activation of 
caspase 9 [48, 73]. Identical to the extrinsic pathway of apoptosis, activation of 
caspase 3 then leads to the downstream induction of apoptosis. 
 Although the EGFR is typically associated with cell growth and 
proliferation, forms of cancer that hyper-express the receptor often undergo 
EGFR-mediated apoptosis. MDA-MB-468 cells are a metastatic breast epithelial 
cell line, derived from the M.D. Anderson Cancer Center in Houston, Texas [74].  
In this cell line, the EGFR is hyper-expressed, with approximately 1.3 X 106 
receptors per cell [75]. Initial studies with this cell line revealed that lower than 
physiological levels of EGF ligand (1 ng/mL) enhance cell growth; however, 
ligand concentrations that exceed 10 ng/mL induce dose dependent decreases in 
cell viability [44] . Studies within the Ceresa laboratory utilizing MDA-MB-468 
cells have shown that when activated and retained at the cell membrane, the 
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EGFR elicits signals for cell growth; however, once internalized within the 
endosomes, the receptor elicits signals for apoptosis. Polystyrene beads of 0.9-
micrometer size covalently conjugated to EGF ligand were used for this 
determination. The polystyrene bead itself is too large for clathrin-mediated 
internalization. The conjugated EGF is able to activate the receptor while the 
bead retains the activated receptor to the cell membrane. Cells treated with EGF 
beads did not activate Caspase 3, where as cells treated with soluble EGF did 
activate Caspase 3.  
Immunoblot analyses from the Ceresa laboratory have disclosed that 
there is a defect in endocytic trafficking within this cell line [76]. Through use of 
Percoll gradient and indirect immunofluorescence assays, Rush et al. have 
shown that instead of traversing the entire endocytic pathway to the lysosome for 
degradation, the EGFR accumulates on the limiting membrane of the early 
endosome in MDA-MB-468 cells. In the same study, HeLa cells, which express 
physiological levels of EGFR and do not undergo EGF-induced apoptosis, were 
treated with Monensin in order to block the acidification of the early endosome. 
This essentially stopped trafficking of the EGFR beyond the endosome, causing 
EGFRs to accumulate in the early endosome, mimicking the same defect found 
in the MDA-MB-468 cell line. Treatment with Monensin and EGF ligand in HeLa 
cells caused the cells to undergo EGFR-mediated apoptosis [77].  
 
In summary, apoptosis and programmed cellular death are normal 
processes within the lifespan of the cell. There are key physiological and 
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morphological features that distinguish apoptotic cells from necrotic and viable 
cells. The EGFR is implicated in apoptosis in cell lines that hyperexpress it. Data 
from the Ceresa laboratory indicate that in addition to undergoing EGFR-
mediated apoptosis, this apoptotic process is spatially regulated within MDA-MB-
468 cells. Progression within this project involves determining all of the 
necessary protein components implicated in EGFR-mediated apoptosis.
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REVIEW OF PKG AND STAT3 
 
There are two major goals of this project: the first being to determine 
whether or not various EGFR ligands induce differential outcomes on viability 
and apoptosis. The second goal was to identify proteins suspected of having 
direct implications in the EGFR-induced apoptotic process in the MDA-MB-468 
cell line. As previously mentioned, it has been shown that low (10 ng/mL) 
concentrations of EGF ligand enhance cell growth within this cell line. Ligand 
concentrations that exceed 10 ng/mL induce cell death [44].  
An EGFR-effector screening was conducted by means of western blot 
analysis, upon exposing MDA-MB-468 cells to low (1 ng/mL) and high (100 
ng/mL) EGF for various time points within a 2-hour period. Additionally, dose 
response experiments were conducted with increasing concentrations of EGF 
ligand for effector determinations as well. Protein effectors downstream of EGFR 
activation were expected to be upregulated with low ligand treatment if they had 
implications in cell growth. Conversely, effectors that were upregulated with high 
ligand treatment were assumed to have implications with cell death. After 
completing the effector screening, only two protein candidates were identified 
with potential correlation to upregulated EGFR with high ligand treatments: PKG 




Cyclic guanosine monophosphate (cGMP), a second messenger protein 
derived from GTP, elicits downstream signaling events through interactions with 
intracellular receptor proteins. It is involved in the regulation of smooth muscle 
tone, bone growth, platelet aggregation, and electrolyte and fluid 
homeostasis[78-80]. Nitric Oxide (NO), produced from nitric oxide synthase, is 
the first component involved in the activation of cGMP. NO activates soluble 
guanylate cyclases (GC-S), which increase cGMP levels. Cyclic-GMP then 
proceeds to bind to and activate a number of downstream substrates [79]. One of 
the more prominent receptor substrates of cGMP is the cGMP-dependent protein 
kinase (PKG). PKG was first discovered in 1970 in the muscle of lobster tails 
[81]. It is a serine/threonine protein kinase whose substrates include receptors, 
enzymes and ion channels [82].  
The binding of 2 cGMP molecules is required for the complete activation 
of one PKG molecule [82]. PKG is a homodimer consisting of two of the same 
monomers, each of which contains a regulatory domain and a catalytic domain 
on one polypeptide chain [78-80, 82] (Fig. 3). Dimerization, auto-inhibition, and 
autophosphorylation all occur at the regulatory domain [79]. The catalytic domain 
contains a conserved threonine residue, whose phosphorylation is critical for 
relieving auto-inhibition, and essentially for kinase activity [79, 83]. PKG exists in 
two homologous forms: PKG I and PKG II. PKG I is localized within the 
cytoplasm whereas PKG II is generally associated with the cell membrane [82]. 
Additionally, there are two isoforms of the type I PKG homologue: PKGIβ and  
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Figure 3. Domain (A) and Crystal (B) Structures of cyclic-GMP-dependent 
protein kinase (PKG). (Domain structure adapted from Francis et al., 







PKGIα. These two isoforms are closely related, except in the N-terminal domain 
of the PKGIα isoform, which has 16 fewer residues than the PKGIβ isoform [82].  
More recently, the NO/cGMP/PKG pathway has been discovered to play 
critical roles in cell proliferation and chemoresistance in cancer cells [84, 85]. 
Studies have shown that cells that express PKGIα and PKGIβ undergo a 
biphasic response when exposed to NO. Exposure to low levels of NO results in 
activation of PKGIα specifically, leading to cell proliferation and suppression of 
apoptosis. This is because the PKGIα isoform has a higher sensitivity to NO than 
the PKGIβ isoform.  Conversely, a high level of NO leads to activation of both 
PKG isoforms, and tends to promote cell apoptosis and suppress cell 
proliferation. It is believed that the activation of PKGIβ by high-level NO 
contributes to the induction of apoptosis in cancer cells [86].   
 There have also been studies correlating EGFR activity and PKG 
activation. When OV2008 cells, an ovarian cancer cell line, were treated with 
increasing EGF ligand concentrations, immunoblot analyses displayed increased 
phosphorylation of serine-239 residue of VASP, a PKG-specific protein substrate. 
Western blot data from this study also exhibit increased phosphorylation of Src, a 
non-receptor tyrosine kinase protein that encodes for the SRC gene. These data 
suggest that activation of the EGFR and subsequent PKG activation occurs in a 
Src-dependent manner [85].  
Recently, activation of PKG by cGMP has become of significant interest  
as a novel molecular tool in the induction of apoptosis in cancer [87]. PKG 
activation has been shown to induce dose dependent decreases in cell viability, 
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as well as time dependent increases in caspases 3 and 9 activity within the MDA-
MB-468 cell line. The reduction in cell viability due to PKG activation was 
remarkably rescued with the addition of a PKG-specific antagonist to the MDA-
MB-468 cells [87]. Therefore, it is of interest to explore the activation of PKG and 
subsequent induction of PKG-mediated apoptosis in regard to EGFR-mediated 
apoptosis. Correlation of these two apoptotic pathways within the MDA-MB-468 
cell line shows potential in identifying a novel protein with direct implications in 
the spatial regulation of the EGFR. 
STAT3 
In addition to PKG, STAT3 signaling was also shown to be upregulated 
with high concentrations of EGF ligand. Signal Transducer and Activator of 
Transcription (STAT) proteins were initially discovered as a family of cytoplasm-
bound transcription factors, which mediate normal cellular responses to growth 
factors, cytokines, and ligands [88, 89]. STAT activation is critical for the 
mediation of certain biological processes, including cell proliferation, survival, 
differentiation, development and inflammation [90]. To date, there are seven 
known members of the STAT family expressed in mammalian tissue: STAT1, 2, 
3, 4, 5a, 5b, and 6. During activation, STAT proteins become phosphorylated at 
their unique critical tyrosine residues (Tyr705 for STAT3). This 
phosphorylation/activation process is mediated by growth factor receptor tyrosine 
kinases, and cytoplasmic kinases [88, 89]. Phosphorylation occurs at the 
cytoplasm, which induces STAT: STAT dimer formation between two monomers 
via SH2 domain interactions. From the cytoplasm, the activated STATS 
! 25!
accumulate in the nucleus, where they initiate and mediate gene transcription by 
binding to DNA response elements [88]. This results in either upregulation or 
downregulation of the biological processes discussed previously, which are 
critical for cellular homeostasis. 
Similarly to the EGFR, STAT proteins are implicated in cell growth and 
proliferation; however, they are upregulated in cancers and have been known to 
induce aberrant signaling in cancer cells. STAT3 has been reported to be 
constitutively phosphorylated in human cancer, and has been shown to promote 
tumor survival and cancer cell progression [90, 91].  Constitutive STAT3 activity 
has been reported in 30-60% of primary mammary malignancies [92]. One study 
reports that MDA-MB-468 cells exhibit constitutive activation of STAT3, and that 
upon inhibition using a pharmacological inhibitor (5,15-DPP), STAT3:DNA 
complexes decrease in a dose dependent manner of inhibitor [93]. These finding 
were not observed among the data described within this thesis.  
Prior to being implicated in cancer, STAT3-programmed cellular death 
was found to be associated with and required for IL-6 induced cell death in 
myeloid leukemia [94] and mammary grand involution [95, 96]. After a woman is 
finished lactating, the involution process must occur in order to return the 
mammary gland to normal size of a “pre-pregnancy” state. This process is reliant 
on the post-translational upregulation of STAT3. This leads to downregulation of 
serine protease inhibitor 2A (Spi2A), and upregulation of cathepsin B. This 
upregulation of cathepsin B leads to the ultimate induction of apoptosis from the 
lysosome [97].  
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It appears as though STAT3 has been shown to play opposing roles in 
mammary tissue. In one instance, it has been shown to potentiate cell growth 
and invasion when constitutively active in cancer cells. Contrastingly, it has been 
implicated in cell death, being required for mammary gland involution, and even 
in leukemia. One of the focuses of this thesis is to define the role and activity of 
STAT3 in MDA-MB-468 cells. 
In summary, cGMP dependent protein kinase (PKG) plays critical roles in 
smooth muscle function and regulation. PKG activity has been implicated in 
breast and ovarian cancer. More importantly, PKG activity has been shown to 
induce apoptosis in a dose dependent manner of a PKG agonist in MDA-MB-468 
cells [98]. Identifying a correlation between PKG-mediated and EGFR-mediated 
apoptosis is therefore of interest for the progression of this research project. 
STAT3 has also been implicated in cancer. Although this protein is often 
associated with cell growth and survival, it is constitutively active in certain breast 
cancers, and required for cell death in certain contexts, such as post-lactation 
mammary gland involution [97]. It is unknown whether or not PKG and STAT3 
have correlations with EGFR-induced apoptosis in MDA-MB-468 cells. It is now 





MATERIALS AND METHODS 
Cell Line 
 MDA-MB-468 cells were acquired from the American Type Culture Collection 
(ATCC) and maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS), 1% penicillin, 1% 
streptomycin, and 2 mM glutamine.  The cells were maintained at incubation 
conditions of 37 ºC in 5% CO2. 
 
Cell Viability Analyses 
1. MTT assay 
MTT assays were conducted in order to assess cell viability utilizing the 
MDA-MB-468 cells. The MTT assay assesses mitochondrial dehydrogenase 
activity based on its ability to cleave the tetrazolium ring of the MTT reagent 
(Sigma Aldrich), and subsequently produce formazan. Only mitochondria of 
viable cells are capable of such cleavage. Cells were plated at a density of 
5,000-10,000 cells with DMEM supplemented with 10% FBS in a 96 well plate. 
After a 48 hour incubation period, the cells were washed with PBS and serum 
starved for 3 hours in DMEM supplemented with 0.2% BSA. The cells were then 
treated with various ligands and reagents in order to induce cell death.  After 
appropriate incubation periods, the MTT reagent (5 mg/mL in PBS) was added to 
each sample within the 96-well plate. The cells were then incubated for 2 hours 
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at 37ºC in the absence of CO2.  An extraction buffer (20% sodium dodecyl 
sulfate, 50% N-dimethylformamide, 50% ddH2O, 80% Acetic Acid, 1M HCl) was 
then added to all samples of the 96-well plate in order to extract and solubilize 
the formazan crystals. After an additional 30-minute incubation with extraction 
buffer at 37ºC in the absence of CO2, the 96-well plate was then analyzed on a 
BioTek Synergy HT plate reader and Gen5 BioTek software, at a wavelength of 
570 nm. The plate was then read a second time after 24 hours at the same 
wavelength.  
2. Alamarblue assay 
Alamarblue assays were also conducted in order to assess cell viability 
within the MDA-MB-468 cells. Resazurin, the active ingredient in the alamarblue 
reagent, is reduced to Resorufin in viable cells. Resorufin is highly fluorescent 
and viable cells enhance this fluorescence, which can be analyzed and quantified 
on a plate reader.  Cells were plated at a density of 10,000 cells in DMEM 
supplemented with 10% FBS in a 96-well plate. After a 48 hour incubation period, 
the cells were washed with PBS and serum starved overnight in serum free 
DMEM. The cells were then treated with reagents in order to induce either cell 
growth or death. The cells were then incubated in the presence of the various 
reagents for 16 hours. The alamarblue reagent was then added as 10% of the 
sample volume prior to a 2 hour incubation period. The 96-well plate was then 
analyzed on a BioTek Synergy HT plate reader and Gen5 BioTek software, at 
wavelengths of 530 nm (excitation) and 590 nm (emission). 
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Cell Lysate Preparation and Immunoblot Analyses.  
Cell lysates were acquired by washing the cells twice in PBS prior to the 
equilibration to 4 ºC and addition of RIPA lysis buffer for cell solubilization (150 
mm NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mm Tris (pH 
8.0), 10 mm sodium pyrophosphate, 100 mm sodium fluoride, 2 mm 
phenylmethyl sulfonyl fluoride). The lysis buffer/cell mixture was then rotated 
end-over-end for 10 min at 4 °C, followed by a 10 minute centrifugation period at 
15,000 x g, also at 4 °C. The protein concentration of the supernatant from each 
sample was then assessed by a BCA assay (Pierce), and samples were 
subjected to a 1:3 dilution in SDS sample buffer. Equivalent amounts of protein 
(20-40 µg) were separated by either a 7.5%, 10% or 12% SDS-PAGE, prior to 
being transferred to nitrocellulose membranes. After being washed in a blocking 
reagent to prevent non-specific antibody binding, the membranes were exposed 
to various primary antibodies overnight at 4 ºC.  The pY99 primary antibody 
(Santa Cruz) was used to detect phosphorylated tyrosine residues of the EGFR. 
The SC-03 primary antibody (Santa Cruz) was used to detect total 
(phosphorylated and non-phosphorylated) EGFR. The α-tubulin (Sigma Aldrich) 
as well as GAPDH (Santa Cruz) primary antibodies were used as loading 
controls to ensure equivalent amounts of protein were loaded into each lane. The 
following antibodies were also employed for studies within this thesis: pY1045 
(Cell Signaling), pSTAT3(Tyr705; Cell Signaling), pSTAT1 (Tyr701; Cell 
Signaling), STAT3 (Cell Signaling), pMAPK (Cell Signaling), pAKT (Cell 
Signaling), pSRC (Cell Signaling), pVASP (Ser239; Cell Signaling), VASP (Cell 
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Signaling) and pBAD (Ser112; Cell Signaling). After a 1-hour incubation period 
with either anti-mouse (for pY99, α-tubulin and GAPDH) or anti-rabbit (for SC-03, 
pSTAT1(Tyr701), pSTAT3(Tyr705) , STAT3, pBAD (Ser112), pVASP(Ser239), 
VASP, pMAPK, pAKT, and pSRC) secondary antibodies, the membranes were 
washed in TBS-Tween and visualized by ECL reagent using a Fotodyne imaging 
system. All western blot data were analyzed and quantified using ImageJ 
software.  
Statistical Analyses 
 Treatment groups within each individual MTT and Alamarblue experiments 
were quantified to the untreated control to generate percent viabilities for each 
experimental condition. These percentages for 3 individual experiments were 
then averaged together. Data acquired from both assays are reported as the 
means of the percent viabilities ±standard error mean (SEM; n=3) unless 
otherwise specified.  An unpaired student t-test was then performed for the 
determination of significance. Each treatment group was compared to the 
untreated, serum free (SF), DMEM control. A p value of less than 0.05 is 
designated significant, and is indicated by a single asterisk (*). A p value of less 
than 0.01 is designated significant, and is indicated by two asterisks (**). A p 
value of less than 0.001 is designated very significant, and is indicated by three 
asterisks (***). A p value of less than 0.0001 is designated extremely significant, 






There were two major goals of this project, the first being to determine 
whether or not EGFR-induced apoptosis is ligand specific. The second goal was 
to identify proteins suspected of having direct implications in the EGFR-induced 
apoptotic process in the MDA-MB-468 cell line.  
 
EGF, BTC, and TGFA ligands induce dose dependent decreases in cell 
viability in MDA-MB-468 cell line. 
  
The purpose of this study was to investigate the possibility that different 
EGFR ligands have differential outcomes on EGFR-mediated viability and or 
induction of apoptosis. To assess this possibility, MDA-MB-468 cells were 
subjected to an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) cell viability assay upon exposure to EGF, BTC, and TGFA ligands for 
16 hours total. All three of these ligands induce a dose dependent decrease in 
cell viability. All ligands showed statistical differences at high (16 nM) 
concentrations when quantified to the serum free DMEM control treated cells 








EGF, BTC, and TGFA all induce a rounded cellular morphology in MDA-MB-
468 cells. 
 
 The purpose of this study was to observe the geometry and morphology of 
the MDA-MB-468 cells after exposure to EGF, BTC, and TGFA ligands. When 
cells undergo apoptosis, they physically shrink in size, and round in morphology. 
We observed the cells at various time points upon exposure to 16 nM 
concentrations of each ligand. With increased time, we observed an increase in 
the amount of rounded cells versus cells with a viable, cobblestone-like 
morphology. At the latest, 24-hour time point, we observed that all cells exposed 
to all three ligands were morphologically rounded (Figure 5). 
 
EGF, BTC, and TGFA induce dose dependent increases in EGFR 
phosphorylation. 
 
 The purpose of this experiment was to expose MDA-MB-468 cells to 
increasing concentrations of EGF, BTC, and TGFA ligands in order to compare 
and contrast any differences in EGFR phosphorylation patterns by means of 
western blot analysis. Cells were exposed to 0, 0.16 nM, 0.5 nM, 1.6 nM, 5 nM, 
and 16 nM concentrations of each ligand for 1 hour. Western blot analyses 
confirm dose dependent increases in EGFR phosphorylation in response to each 






Figure 4. EGF, BTC, and TGFA ligands induce dose dependent decreases 
in cell viability in MDA-MB-468 cell line. 
Results from an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) cell viability assay. EGF, BTC, and TGFA ligands all induce a dose 
dependent decrease in cell viability in the MDA-MB-468 cell line. Data are means 
of percent viability ± SEM (n=4). Data were subjected to an unpaired student T-
Test, each being compared to the untreated, serum free media control. An 














































Figure 5. EGF, BTC, and TGFA ligands each induce a rounded cellular 
morphology in MDA-MB-468 cells. 
Cells were exposed to 16 nM concentrations of each ligand and then incubated 
for 24 hours total. Photomicrographs (20x) were taken at times 0h, 8h, 16h, and 
24h on a Nikon Eclipse Ti Eclipse widefield epifluorescence microscope.  








Figure 6. EGF, BTC, and TGFA induce dose dependent increases in EGFR 
phosphorylation. 
After harvesting the cell lysates, 40 µg of protein from each sample were 
resolved on a 7.5% SDS-PAGE. The protein was then transferred to a 
nitrocellulose membrane, which was then immunoblotted for either total 
phosphotyrosine containing proteins (p-EGFR) (pY99), Total EGFR (Sc-03), or 
loading control, α-Tubulin. After incubation with appropriate secondary 















Identifying differences in EGFR-effector signaling between low (1 ng/mL) 
and high (100 ng/mL) EGF ligand exposures.  
 
The purpose of this experiment was to expose MDA-MB-468 cells to low 
and high EGF concentrations in order to identify any differences in 
phosphorylation patterns and effector signaling. As previously mentioned, MDA-
MB-468 cells undergo cell growth when exposed to low (1 ng/mL) concentrations 
of EGF, and apoptosis when exposed to high (≥10 ng/mL) EGF concentrations. 
The goal was to subject the cells to both low and high ligand, and then look at 
effector signaling in order to identify and differentiate effectors associated with 
cell growth, versus those associated with apoptosis. Cells were exposed to each 
of the ligand concentrations at various time points for a total of 120 minutes. 
Immunoblot analyses allowed for the assessment of pY1045, EGFR, pMAPK, 
pAKT, pSRC, pBAD, p-VASP-SER239, and GAPDH (Figure 7).  
Mitogen-activated protein kinase 1 (MAPK), Proto-oncogene tyrosine-
protein kinase sarcoma (SRC), Protein Kinase B (AKT), and Bcl-associated 
Death Protein (BAD) exhibit no significant differences in EGFR signaling at 
low versus high ligand concentrations.  
These data are a quantification of three separate experiments of the 
western blot data, represented in figure 7. Western blot data of all four effectors 
were quantified to the loading control for each experiment, GAPDH. No 
significant differences between low and high ligand exposures could be 
determined in phosphorylated, (p)-MAPK (Figure 8A), p-AKT (Figure 8B), p-SRC 






Figure 7. Identifying differences in EGFR-effector signaling between low  
(1 ng/mL) and high (100 ng/mL) EGF ligand exposures.  
After harvesting the cell lysates, 20 µg of protein from each sample were 
resolved on a 12% SDS-PAGE. The protein was then transferred to a 
nitrocellulose membrane, which was then subjected to immunoblot analyses, to 
assess for pY1045, EGFR, pMAPK, pAKT, pSRC, pBAD, p-VASP-SER239, and 
GAPDH phosphorylation. After incubation with appropriate secondary antibodies, 



























Figure 8. MAPK, SRC, AKT, and BAD exhibit no significant differences in 
EGFR signaling at low versus high ligand concentrations.  
Quantification of three separate experiments of the western blot data represented 
in Figure 7. Error bars are expressed as ± SEM. No significant differences in 
signaling between low and high EGF ligand exposures could be determined in 





















































































Increases in EGF ligand concentration elicit a dose dependent increase in 
p-VASP(SER239) phosphorylation.  
 
 The purpose of this experiment was to assess PKG activity, by means of a 
p-VASP-SER239 antibody, in order to determine if its activity had any correlation 
with EGFR activity. A dose response was conducted, using 0, 1, 3, 10, 30 and 
100 ng/mL concentrations of EGF ligand. Data confirm that increases in EGF 
ligand induce dosed dependent increases in p-VASP-SER239 phosphorylation 
(Figure 9A). Western blot analyses of pY1045 and p-VASP-Ser239 from 3 
experiments were both analyzed and quantified to western blots of total EGFR 
and total VASP respectively (Figures 9B and 9C). Data from figure 9D are a 
quantification of three experiments of the p-VASP-SER239 western blot data, 
represented in Figure 7. 
PKG agonist, 8-Bromo-cGMP, induces a dose dependent decrease in cell 
viability.  
 
 The purpose of this experiment was to assess PKG-activation and its 
potential role in the induction of apoptosis in MDA-MB-468 cells. Literature has 
shown that PKG is able to induce apoptosis within this cell line. It was of interest 
to determine if PKG induction of apoptosis had correlation to EGFR-induced 
apoptosis. We decided to first assess cell viability by means of an MTT assay in 
order to configure an optimal concentration for Annexin V assay, a more accurate 
measure of apoptosis. MDA-MB-468 cells were subjected to increasing 
concentrations (100 µM, 300 µM, 500 µM, 1 mM, 3 mM, 10 mM) of PKG 
activator, 8-Bromo-cGMP (8-Br-cGMP; Sigma) for 48 hours total. Cells treated in 









Figure 9. Increases in EGF ligand concentration elicit a dose dependent 
increase in p-VASP(SER239) phosphorylation.  
A dose response was conducted, using 0, 1, 3, 10, 30 and 100 ng/mL 
concentrations of EGF ligand. Cells were exposed to the 5 different ligand 
concentrations for 30 minutes. Twenty µg of protein per sample were then 
resolved on a 12% SDS-PAGE (A). Western blot data of p-VASP-SER239 (B) 
and pY1045 (B) blot membranes were quantified to total VASP and total EGFR, 
respectively. Data from Figure 9D are a quantification of three experiments of the 
p-VASP-SER239 western blot data, represented in Figure 7. Error bars are 





































































DMEM (SF) and DMEM supplemented in 10% FBS (10% FBS) served as 
positive controls for viability. Cells treated with 16 nM EGF and 100 nM 
Staurosporine (STS) served as negative controls for viability, and positive 
controls for apoptosis. Data from this experiment exhibit a clear dose dependent 
decrease in MDA-MB-468 cell viability in response to the dose dependent 
increases in PKG activation (Figure 10). 
 
The use of PKG agonist, 8-Bromo-cGMP, confirms that PKG does not elicit 
EGFR phosphorylation.  
 
 The purpose of this experiment was to assess the efficacy of commercially 
available PKG inhibitors, as well as the ability of a PKG agonist to activate the 
EGFR. The only way of determining if PKG plays a true intermediary role in 
EGFR-induced apoptosis is to reduce PKG activity, and then subsequently 
assess this effect on apoptosis and viability. The PKG antagonist, (D)-DT-2 
(Biolog Life Science Institute; IC50 ~12 nM) was used at 1.25 nM, 12.5 nM, 25 
nM, 125 nM, 500 nM, and 1.25 µM concentrations. The PKG agonist, 8-Br-
cGMP, was used at 10 µM, 30 µM, 100 µM, 300 µM, 1 mM, and 3 mM 
concentrations, with an accompanying vehicle control comprised of 33% ddH2O. 
The 8-Br-cGMP agonist was employed within this assay as a positive control for 
pVASP(Ser239) phosphorylation, whereas cells treated in serum free DMEM 
(SF) served as negative controls for EGFR (pY1045) and pVASP(Ser239) 
phosphorylation (Figure 11A).  The PKG antagonist, Rp-8Br-PET-cGMPs (Biolog 
Life Science Institute; IC50 ~25 µM) was used at 1 µM, 3 µM, 10 µM, 30 µM, and 
100 µM concentrations, with an accompanying vehicle control comprised of 
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0.38% Dimethylformamide (DMF) in DMEM (Figure 11B). The PKG agonist, 8-
Br-cGMP, was used at 300 µM, 1 mM, 1.3 mM, 2 mM, and 3 mM concentrations, 
with an accompanying vehicle control comprised of 33% ddH2O in DMEM. The 8-
Br-cGMP agonist was employed within this assay as a positive control for 
pVASP(Ser239) phosphorylation, whereas cells treated in serum free DMEM 
(SF) served as negative controls for EGFR (pY1045) and pVASP(Ser239) 
phosphorylation (Figure 11B).  Although neither antagonist functioned as 
sufficiently as anticipated, it is clear that PKG activation with 8-Bromo-cGMP 
does not induce EGFR (pY1045) phosphorylation and subsequent activation.  
 
PSTAT3(Tyr705) is upregulated in both a dose and time dependent manner, 
at high EGF ligand concentrations.  
 
The purpose of these experiments was to assess STAT3 signaling when 
exposed to low and high EGF concentrations. STAT3 was one of the proteins 
assessed in our initial EGFR-effector screening. MDA-MB-468 cells were 
subjected to 2-hour time course experiments (Figure 12A. and 12B.), and 30-
minute dose response experiments (Figure 12C. and 12D.) at low and high 
ligand concentrations, as described previously. Data confirm that both STAT1 
and STAT3 are upregulated in a time dependent manner, at 100 ng/mL EGF 
ligand concentrations. At 1 ng/mL EGF, minimal STAT1 activation and no STAT3 
activation was observed. Data from dose response experiments, utilizing 1, 3, 10, 




Figure 10.  
 
  
Figure 10. Dose dependent increase in PKG activator, 8-Bromo-cGMP, 
induces a dose dependent decrease in cell viability. 
Results from an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) cell viability assay. Increasing concentrations of a PKG activator induce 
a dose dependent decrease in cell viability within the MDA-MB-468 cell line after 
48 hours. Data are means of percent viability ± SEM (n=3). Data were subjected 
to an unpaired student T-Test, each being compared to the untreated, serum free 
(SF) DMEM control. An asterisk (*) indicates a significance of p<0.05.   **, 






















































































Figure 11. The use of PKG agonist, 8-Bromo-cGMP, confirms that PKG 
does not elicit EGFR phosphorylation.  
A. The PKG antagonist, (D)-DT-2 (IC50 ~12 nM) was used at 1.25 nM, 12.5 nM, 
25 nM, 125 nM, 500 nM, and 1.25 µM concentrations. The PKG agonist, 8-Br-
cGMP, was used at 10 µM, 30 µM, 100 µM, 300 µM, 1 mM, and 3 mM 
concentrations, with an accompanying vehicle control (VC) comprised of 33% 
ddH2O in DMEM. Forty µg of protein per sample were then resolved on a 12% 
SDS-PAGE.  
B. The PKG antagonist, Rp-8Br-PET-cGMPs (IC50 = 25 µM) was used at 1 µM, 3 
µM, 10 µM, 30 µM, and 100 µM concentrations, with an accompanying vehicle 
control comprised of 0.38% Dimethylformamide (DMF). The PKG agonist, 8-Br-
cGMP, was used at 300 µM, 1 mM, 1.3 mM, 2 mM, and 3 mM concentrations, 
with an accompanying vehicle control (VC) comprised of 33% ddH2O in DMEM. 




























Figure 12. pSTAT3(Tyr705) is upregulated in both a dose and time 
dependent manner, at high EGF ligand concentrations.  
A. MDA-MB-468 cells were subjected to a 2-hour time course experiment, 
and were exposed to 1 ng/mL and 100 ng/mL EGF concentrations at various 
time points within the 2-hour window frame (0, 15, 30, 60, 90, and 120 
minutes). Thirty µg of protein per sample were then resolved on a 12% SDS-
PAGE. 
B. Quantification of three independent time course experiments, represented 
in figure 12A. Error bars are expressed as ± SEM.  
C. The cells were also subjected to a 30-minute dose response experiment, 
and were exposed to ligand concentrations of 1, 3, 10, 30 and 100 ng/mL 
EGF.  
D. Quantification of three independent dose response experiments, 





























































Commercially available STAT3 antagonists exhibit non-specific inhibition 
of STAT3 in MDA-MB-468 cells. 
 
The purpose of these experiments was to utilize 2 commercially available 
STAT3 inhibitors in order to examine the role of STAT3 in the induction of EGFR-
mediated apoptosis. MDA-MB-468 cells were exposed to increased 
concentrations of 5,15-DPP (Sigma; IC50= 280 nM; Figure 13A.) and STATTIC 
(Sigma; IC50= 5.1 µM; Figure 13B.) STAT3 inhibitors. In addition to the dose 
dependent decrease in pSTAT3(Tyr705) that each inhibitor induced, both 
inhibitors also induced dose dependent inhibition of phosphorylated EGFR 
(pY1045).  
STATTIC induces a dose dependent decrease in cell viability. 
 Upon completion of dose response, western blot experiments with the 
STATTIC inhibitor, cytotoxicity was observed with each utilized concentration of 
inhibitor. Therefore, Alamarblue, cell viability experiments were employed in 
order to assess and quantitate the extent of toxicity STATTIC induced within 
MDA-MB-468 cells. STATTIC was reconstituted in DMF and cells were treated 
with an accompanying vehicle control of 0.31% DMF in DMEM (Figure 14A). It 
was also of interest to determine if STATTIC used in combination with 100 ng/mL 
EGF ligand induced more apoptosis than STATTIC alone. Alamarblue 
experiments confirm that with low (3 µM) STATTIC, 100 ng/mL of EGF appears 
to slightly enhance the extent of apoptosis; however, the concentrations of both 
EGF and STATTIC alone induced over 50% cell death. Therefore, it was not 
possible to fully describe the interaction of the two components in combination 






Figure 13. Commercially available STAT3 antagonists exhibit non-specific 
inhibition of STAT3 in MDA-MB-468 cells. 
A. A dose response experiment was conducted, utilizing 30 nM, 100 nM, 300 
nM, and 1 µM concentrations of the 5,15-DPP STAT3 inhibitor. Cells were 
also treated with a vehicle control (VC) of 0.34% DMF in DMEM. Upon 
harvesting cell lysates, 40 µg of protein per sample were then resolved on 
a 12% SDS-PAGE. 
B.  A second STAT3 inhibitor, STATTIC, was employed at 1 µM, 3 µM, 10 
µM, 30 µM, and 100 µM concentrations. The cells were also treated with a 
vehicle control (VC) of 0.38% DMF in DMEM. Upon harvesting cell 

































Figure 14. STATTIC induces a dose dependent decrease in cell viability. 
A. STAT3 inhibitor, STATTIC, was employed in order to examine and 
quantify its extent of cytotoxicity. EGF and staurosporine treatments 
served as positive controls for apoptosis (n=2 ± SEM). B. STATTIC was 
used in combination with 100 ng/mL EGF ligand to determine if the 




































































siRNA targeting STAT3 are able to significantly reduce STAT3 activity. 
 
 The purpose of this experiment was to determine if MDA-MB-468 cells 
could be subjected to siRNA knockdown. This determination is critical for 
employment of subsequent siRNA, and subsequent analysis of cell viability and 
apoptosis. In order to assess this, siRNA targeting STAT3 (Dharmacon; SO-
2427018G) were employed. Western blot analyses confirm that with the addition 
of both STAT3 siRNA, vast reduction in phosphorylated and total STAT3 (78% 
reduction) is observed in MDA-MB-468 cells (Figure 15).  
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Figure 15. siRNA targeting STAT3 are able to significantly reduce STAT3 
activity. MDA-MB-468 cells were subjected to 50 nM and 100 nM STAT3 siRNA 
for 72 and 96 hours. After allotted time points, cells were harvested, and 20 µg of 


















Initial intentions of this study were to understand the molecular 
mechanisms that elicit EGFR-mediated apoptosis.  In doing so, MDA-MB-468 
cells were exposed to various endogenous EGFR ligands and determine their 
individual outcomes on cell viability. It was of interest to determine if the EGFR 
had ligand specificity within this cell line. Knowing that EGF, BTC, and TGFA 
ligands each cause differential endocytic sorting of the receptor [35], it is possible 
that these ligands can differentially affect cell viability and apoptosis as well. If 
the ligands induce different cellular morphologies and phenotypes, this 
information could be useful in determining how the EGFR is spatially regulated 
within this cell line. We decided to first assess cell viability in order to determine 
optimal time points and concentrations for subsequent apoptosis analyses. 
Results from the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) cell viability assay confirm that the MDA-MB-468 cells undergo dose 
dependent decreases in cell viability in response to all three ligands (Figure 4). 
Cell morphology was assessed upon exposure of the MDA-MB-468 cells 
to high (16 nM) concentrations of each ligand. When cells undergo cell death, 
they tend to round morphologically. We wanted to physically assess the condition 
of the cell by taking bright field images of the cells with increased time. The 24-
hour images of each of the three-ligand treatment groups showed the same 
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rounded cellular morphologies, indicative of cell death (Figure 5). These data 
confirm the findings within the MTT analyses.  
 Lastly, phosphorylation patterns were assessed after exposure to 
increasing concentrations of each ligand (0, 0.16 nM, 0.5 nM, 1.6 nM, 5 nM, 16 
nM). This assay was conducted in order to assess for any variations in EGFR 
phosphorylation patterns. Although BTC ligand had slightly reduced 
phosphorylation in comparison to EGF and TGFA ligands, all 3 ligands induced 
dose dependent increases in phosphorylation, with similar phosphorylation 
patterns (Figure 6).  
From these three experiments, we can confidently confirm that different 
EGFR ligands do not induce any variation in cell integrity or morphology within 
the MDA-MB-468 cell line. All three of these ligands induce cell death 
morphology, decreases in cell viability, and have similar EGFR phosphorylation 
patterns within our cell line of interest. Therefore, we conclude that EGFR-
mediated apoptosis from the endosomes is not ligand specific. This 
determination means that there is a requirement for a different experimental 
approach in order to understand the effector proteins and mechanisms involved 
in EGFR-mediated apoptosis and spatial regulation.   
The findings within these studies were ultimately anticipated. We suspect 
that EGFR-mediated apoptosis is a regulatory mechanism of cancers that hyper-
express this receptor. Low concentrations of EGF ligand results in a lower ratio of 
activated receptors, leading to cell growth. Conversely, with high EGF ligand 
concentrations, a larger amount of receptors are activated, and cell death occurs 
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[44]. We speculate that in MDA-MB-468 cells, high ligand levels elicits high 
receptor activation at cell membrane, resulting in the need for an immense level 
of ligand:receptor internalization and trafficking at the same time. The endocytic 
machinery required for the internalization and trafficking of the receptor is 
incapable of efficiently sorting the large number of ligand:receptor complexes, 
causing  saturation of the endocytic machinery. As a result of this saturation, the 
increasingly high levels of activated receptors accumulate at the early endosome. 
This causes a disruption in normal cell homeostasis, inevitably resulting in 
apoptosis. We ultimately hypothesize that the accumulation at the endosome as 
a result of high receptor activation is the underlying culprit of EGFR-mediated 
apoptosis in the MDA-MB-468 cell line. Therefore, higher levels of any natural 
receptor ligand will still deduce the same extent of receptor activation, and result 
in cell death.  
It is known that the biological sequence of receptor tyrosine kinases 
entails the recruitment of downstream signaling molecules to the phosphorylated 
tyrosine residues of the activated receptor dimer [4]. These signaling molecules 
are often intermediates in signaling cascades that are ultimately responsible for 
cell growth, migration, and in our case apoptosis. Upon EGFR activation, and 
internalization within the MDA-MB-468 cell line, we speculate that endosomal 
accumulation of the receptor results in the recruitment of resident proteins, and 
which are ultimately responsible for initiating the downstream signaling cascade 
for the induction of apoptosis. Identifying the kinases/proteins that are recruited 
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specifically for the induction of apoptosis is an ideal manner of determining how 
the EGFR is spatially regulated in MDA-MB-468 cells, and in cancer.  
 In addition to the EGFR, activation of cyclic GMP-dependent protein 
kinases (PKGs) has been shown to induce dose dependent increases in 
apoptosis in MDA-MB-468 cells [98]. Data from our MTT assay, utilizing a potent 
activator of PKG (8-Bromo-cGMP) in MDA-MB-468 cells, indicate that increasing 
concentrations of the PKG activator result in dose dependent decreases in cell 
viability (Figure 10). Our findings from this MTT assay complement the findings 
from the literature, and present us with a kinase candidate with a plausible role in 
EGFR-mediated apoptosis. Western blot analyses confirm that with the addition 
of increasing concentrations of EGF ligand, a dose dependent increase in PKG 
activation is observed, by means of a pVASP(Ser239) antibody. Western blot 
analyses also confirm that with addition of 3 mM 8-Bromo-cGMP, PKG agonist, 
activation of PKG is observed, however, no EGFR phosphorylation in observed. 
This is indicative that PKG is downstream of and activated in a dose dependent 
manner by the EGFR.  Commercially available PKG antagonists, (D)-DT-2 and  
Rp-8-Br-PET-cGMPs, did not sufficiently inhibit PKG activity within the MDA-MB-
468 cell line. The lack of inhibition could be due to the fact that the EGFR is 
directly phosphorylating VASP at the serine 239 residue. It is now clear that 
siRNA targeting PKG must be employed in order to assess this possibility.     
Confirming or refuting PKG as an intermediate in EGFR-mediated apoptosis in 
MDA-MB-468 cells is the next step in defining the regulatory mechanisms of the 




Figure 16. Working model for how EGFR-induced apoptosis occurs in a 
PKG-mediated manner. The speculation is that PKG is a resident kinase of the 
early endosome that is recruited to elicit downstream signaling pathways that 

















It was also of interest to attempt to find other protein candidates that could 
potentially be implicated in EGFR-induced apoptosis. Because of this, an EGFR-
effector screening was conducted. Five proteins, MAPK, AKT, SRC, BAD, and 
STAT3 were selected due to their differential roles in various, downstream cell 
signaling pathways. Each of these effectors has been implicated with the EGFR 
and apoptosis. As previously mentioned, MDA-MB-468 cells undergo cell growth 
when exposed to low (1 ng/mL) concentrations of EGF, and apoptosis when 
exposed to high (10 ng/mL) EGF concentrations. The goal was to subject the 
cells to 2-hour time course experiments with low and high ligand, and then look 
at signaling within the 5-effector proteins in order to identify and differentiate 
effectors associated with cell growth (preferential signaling with low ligand), 
versus those associated with apoptosis (preferential signaling with high ligand). 
We determined that there was no significant difference in signaling between low 
and high EGF concentrations among pAKT, pMAPK, pSRC, and pBAD (Figure 
7). Therefore, we chose not to pursue these four proteins for subsequent studies.  
The MDA-MB-468 cells were also subjected to dose response 
experiments with EGF ligand, and then subsequent western blot analyses of the 
dose response experiments. Two protein candidates showed to be dynamically 
upregulated in an EGFR dose dependent manner: PKG and STAT3 (Figure 9A 
an Figure 12C, respectively). Data within this thesis do not indicate that STAT3 is 
constitutively active. Both, dose response and time course data confirm that 
STAT3 is inactive at low concentrations, and preferentially activated at high 
concentrations of EGF (Figure 12A and Figure 12B).  This suggests that the 
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EGFR is activating STAT3 at the high EGF concentrations as an intermediate in 
the induction of apoptosis. However, it cannot be ruled out that STAT3 is being 
activated as a compensatory mechanism, in an attempt to rescue the cell from 
EGFR-mediated apoptosis.  
In order to assess the role of STAT3 in EGFR-induced apoptosis, two 
different STAT3 inhibitors were employed: 5,15-DPP and STATTIC. Although the 
5,15-DPP inhibitor was not cytotoxic, it inhibited the EGFR, more than pSTAT3 
(Figure 13A). Findings among this thesis also contradict that of the literature, 
which reports no reduction in pSTAT3(Tyr 705) phosphorylation with 50 µM 
treatment of 5,15-DPP in MDA-MB-468 cells [93]. Similarly to 5,15-DPP, 
STATTIC also antagonized the EGFR in a dose dependent manner, completely 
blocking EGFR activation at 100 µM. Unlike 5,15-DPP, STATTIC was however 
cytotoxic (Figure 14A). An Alamarblue experiment utilizing STATTIC confirmed a 
dose dependent decrease in cell viability in response to the STATTIC reagent. 
STATTIC was also assessed in combination with a fixed concentration (100 
ng/mL) of EGF ligand. If STAT3 is being activated as a compensatory 
mechanism, in favor of cell survival, inhibition of STAT3 with the addition of EGF 
ligand should potentiate the induction of apoptosis, more than STATTC or EGF 
alone. The dose response curve of STATTIC + EGF did seem to potentiate a 
decrease in cell viability, but only at low (3 µM) STATTIC concentrations. This is 
believed to be due to the fact that at high concentrations, STATTIC inhibits 
activation of the EGFR. Potentiation of cell death of the cells exposed to 
STATTIC in combination with EGF would not be an expected observation at high 
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STATTIC concentrations, because of the minimal EGFR activity occurring. In 
order to accurately assess the role of STAT3 in EGFR-induced apoptosis, siRNA 
targeting STAT3 must be employed. Through use of readily available siRNA, 
targeting STAT3, it can confidently be confirmed that MDA-MB-468 cells are 
cable of being subjected to siRNA transfections (Figure 15).  
The current model for the role of STAT3 in EGFR-induced apoptosis in 
MDA-MB-468 cells exists as 2 scenarios (Figure 17). In the left panel; STAT3 is 
an intermediate in EGFR-induced apoptosis. Similarly to the involution process, 
STAT3 is upregulated, which causes the post-translational upregulation of 
cathepsin B. Cathepsin B upregulation leads to lysosomal induction of apoptosis. 
Conversely, in the right panel, STAT3 is upregulated in an attempt to rescue the 
cell from EGFR-induced apoptosis. In this portion of the model, STAT3 might be 
upregulated, specifically at high concentrations as a “rescue mechanism” to 
avoid the cell undergoing apoptosis. This mechanism inevitably fails, however, 
which is evidenced by the fact the EGFR-mediated apoptosis occurs in the MDA-





Figure 17. Two models describing the potential roles of STAT3 in EGFR-
induced apoptosis in MDA-MB-468 cells. (Adapted from Resemann et al., 

























SUMMARY AND CONCLUSIONS 
 
The research conducted within this thesis attempts to identify any ligand 
specificity in EGFR-mediated apoptosis in MDA-MB-468 breast cancer cells. Cell 
viability, EGFR-phosphorylation patterns, and cell morphology were all assessed 
in the MDA-MB-468 cell line upon exposure to EGF, BTC, and TGFA ligands.  All 
of the ligands induce dose dependent decreases in viability, as well as dose 
dependent increases in EGFR-phosphorylation. Each of the ligands induced 
rounded cellular morphologies at high concentrations. These findings are 
indicative that there is no ligand specificity in regard to EGFR-mediated 
apoptosis within this cell line, and that these cells undergo cell death when 
exposed to the 3 ligands. This work helped to unveil the roles of endogenous 
EGFR ligands in receptor trafficking and overall cell viability. However, a different 
approach had to be employed in order to further understand how the receptor is 
spatially regulated within our cell line of interest.  
Due to time course and dose response experiments, two protein 
candidates have been identified to potentially play an intermediary role in EGFR-
induced apoptosis: PKG and STAT3. Ideally, it is of interest to silence each 
protein within MDA-MB-468 cells, activate the EGFR, and evaluate their 
individual roles in EGFR-mediated apoptosis. Commercially available inhibitors of 
both proteins have shown not to properly antagonize their functions. 
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Therefore, siRNA knockdown of both PKG and STAT3 will be employed for 
subsequent analyses. Sufficient inactivation of PKG and STAT3 will be verified 
through immunoblot analyses of total STAT3 and total VASP proteins.  
 
STRENGTHS OF THIS WORK 
 The major strength of this work lies within use of MDA-MB-468 cell line. 
This cell line expressed over one million EGFRs per cell. High receptor 
expression will elicit high receptor activation, which is ideal for immunoblot 
analysis and ultimate assessment of EGFR phosphorylation. It is also 
advantageous that this cell line has a defect in endocytic trafficking, causing the 
EGFR to accumulate within the early endosome. This allows for a clear, 
manageable determination of EGFR signaling at the subcellular level. Studying 
EGFR endocytic trafficking in cells that traffic the receptor efficiently requires the 
use of pharmacological reagents to trap the receptor at the desired subcellular 
location. Such use of these reagents are not required due to the natural defect 
the cells obtain upon EGFR activation and internalization. Overall, this cell line 
has a natural, tractable response in regard to EGFR activation, allowing for a 
more manageable model to study receptor trafficking and signaling. 
 
LIMITATIONS AND WEAKNESSES  
 Studies conducted at the cellular level have some unavoidable limitations. 
We are assessing the EGFR:ligand interaction solely in our cell line of interest, 
and not in vivo.  An animal model more accurately recapitulates a human with 
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metastatic breast cancer more so than a tissue culture model. An animal or 
human model is the only manner of determining if exposure to EGFR ligands has 
any effects other than the intended cancer tissue. A tissue culture experimental 
model is ideal for preliminary studies, but a major progression within this study 
and project would be to assess the findings in a more molecularly complex 
organism. Another limitation within this work lies in the use of pharmacological 
inhibitors. Data within this thesis confirm that inhibitors can often not antagonize 
sufficiently (D-DT-2 and Rp-8-Br-PET-cGMPs), or have non-specific, pleiotropic 
effects on other proteins (5,15-DPP and STATTIC). This is a common finding and 
hindrance when conducting scientific research.  Due to this, we will employ 
siRNA to specifically target PKG and STAT3 for sufficient inactivation of each 




The ultimate goal is continuously to determine receptor:effector 
relationships that have implications in EGFR-induced apoptosis. Therefore, 
siRNA knockdown of both PKG and STAT3 will be employed for subsequent 
analyses of the role of each protein in EGFR-induced apoptosis within the MDA-
MB-468 cell line. Further advancement of this project will also rely on determining 
if these 2 proteins are spatially regulated within this cell line. This will require 
synthesis and employment of EGF ligand, covalently conjugated to polystyrene 
beads. This molecular tool will allow us to differentiate signaling occurring at the 
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